(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.
from Reuters: Health News http://ift.tt/2F6WYV3
No comments:
Post a Comment